BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Special Report

Australia Approves First RNAi Therapy For Familial Chylomicronemia Syndrome

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...

May 05, 2026 | Report

WuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report

Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing gov...

May 01, 2026 | News

Haier Biomedical Reports Strong Global Growth As AI Driven Strategy Advances Premium Brand Leadership

AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent...

May 01, 2026 | News

Berlin Heals Reports Positive First In Human Results For Less Invasive CMIC Therapy In Heart Failure

High Impact Session presented at Heart Rhythm Society's Congress in Chicago First time showing results of new Less Invasive approach Improvement in Lef...

April 27, 2026 | News

Engineering Precision In Chromatography From Development To Commercial Scale

Chromatography in Bioprocessing For pilot and commercial purification of monoclonal antibodies and recombinant proteins, chromatography remains the centra...

April 24, 2026 | Analysis

Everest Medicines Reports Promising First In Human Data For Personalised mRNA Cancer Vaccine EVM16

Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presen...

April 24, 2026 | News

EpiBiologics Advances Tissue Selective EGFR Degrader EPI 326 Into First In Human Clinical Study

First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...

April 21, 2026 | News

Synthetic Design Lab Introduces Logic Gated SYNTHBODY Platform Redefining Precision Protein Therapeutics

SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively chang...

April 20, 2026 | News

PFAS Testing Enters A New Era As Solvent Purity And Analytical Discipline Redefine Data Integrity

PFAS analysis has moved from a specialist capability to a core requirement for environmental control and testing laboratories because regulatory values are...

April 21, 2026 | News

Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, impr...

April 08, 2026 | News

Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Color...

April 03, 2026 | News

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Takeda Reports Strong Phase 3 Results For Zasocitinib In Plaque Psoriasis

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...

March 30, 2026 | News

BrightGene Reports Positive Phase 1 Results For Oral GLP 1 GIP Agonist BGM0504

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing BrightGene Bio-Medical Technology C...

March 26, 2026 | News

Stay Connected